$IOVA
IOVANCE BIOTHERAPEUTICS, INC.

2024 Q3 Form 10-Q Financial Statement

#000155837024011641 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $58.56M $31.11M
YoY Change 12385.07% 12969.75%
Cost Of Revenue $39.82M $31.37M
YoY Change 817.58% 1430.15%
Gross Profit $18.73M -$262.0K
YoY Change -583.91% -85.54%
Gross Profit Margin 31.99% -0.84%
Selling, General & Admin $42.62M $41.87M
YoY Change 58.08% 90.93%
% of Gross Profit 227.51%
Research & Development $68.25M $62.08M
YoY Change -22.03% -28.1%
% of Gross Profit 364.32%
Depreciation & Amortization $3.000M $3.000M
YoY Change 3.45% -38.32%
% of Gross Profit 16.02%
Operating Expenses $68.25M $62.08M
YoY Change -22.03% -42.66%
Operating Profit -$89.07M -$101.9M
YoY Change -24.75% -7.42%
Interest Expense $4.005M $3.355M
YoY Change 19.2% 8.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$85.06M -$98.56M
YoY Change -26.04% -7.89%
Income Tax -$1.500M -$1.500M
% Of Pretax Income
Net Earnings -$83.54M -$97.10M
YoY Change -26.56% -8.85%
Net Earnings / Revenue -142.67% -312.16%
Basic Earnings Per Share -$0.28 -$0.34
Diluted Earnings Per Share -$0.28 -$0.34
COMMON SHARES
Basic Shares Outstanding 303.5M 279.8M
Diluted Shares Outstanding 303.3K 284.8K

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $397.5M $412.5M
YoY Change 9.99% 64.43%
Cash & Equivalents $164.2M $228.7M
Short-Term Investments $233.3M $183.9M
Other Short-Term Assets $6.744M $10.26M
YoY Change -43.8% -27.92%
Inventory $38.58M $27.85M
Prepaid Expenses
Receivables $55.77M $31.60M
Other Receivables $0.00 $0.00
Total Short-Term Assets $498.6M $482.3M
YoY Change 30.32% 75.44%
LONG-TERM ASSETS
Property, Plant & Equipment $112.5M $111.0M
YoY Change -0.55% -38.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $280.0K $327.0K
YoY Change -0.71% -99.51%
Total Long-Term Assets $492.5M $482.1M
YoY Change 4.86% -0.07%
TOTAL ASSETS
Total Short-Term Assets $498.6M $482.3M
Total Long-Term Assets $492.5M $482.1M
Total Assets $991.1M $964.3M
YoY Change 16.29% 27.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $31.69M $20.42M
YoY Change 64.4% -34.47%
Accrued Expenses $74.82M $61.79M
YoY Change 22.23% 7.48%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $118.1M $93.64M
YoY Change 29.8% 5.64%
LONG-TERM LIABILITIES
Long-Term Debt $1.000M $1.000M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $66.39M $69.25M
YoY Change -2.37% 0.58%
Total Long-Term Liabilities $99.60M $102.1M
YoY Change 14.03% 46.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $118.1M $93.64M
Total Long-Term Liabilities $99.60M $102.1M
Total Liabilities $217.7M $195.8M
YoY Change 22.07% 9.54%
SHAREHOLDERS EQUITY
Retained Earnings -$2.306B -$2.222B
YoY Change 21.62% 24.7%
Common Stock $13.00K $12.00K
YoY Change 18.18% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $773.5M $768.5M
YoY Change
Total Liabilities & Shareholders Equity $991.1M $964.3M
YoY Change 16.29% 27.34%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$83.54M -$97.10M
YoY Change -26.56% -8.85%
Depreciation, Depletion And Amortization $3.000M $3.000M
YoY Change 3.45% -38.32%
Cash From Operating Activities -$58.97M -$98.43M
YoY Change -29.86% 4.77%
INVESTING ACTIVITIES
Capital Expenditures $2.288M $442.0K
YoY Change -36.09% -95.36%
Acquisitions
YoY Change
Other Investing Activities -$46.51M $40.66M
YoY Change -38.34% -127.61%
Cash From Investing Activities -$48.80M $40.22M
YoY Change -38.24% -125.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.95M 152.8M
YoY Change -79.31% 14809.76%
NET CHANGE
Cash From Operating Activities -58.97M -98.43M
Cash From Investing Activities -48.80M 40.22M
Cash From Financing Activities 41.95M 152.8M
Net Change In Cash -65.82M 94.62M
YoY Change -265.79% -137.89%
FREE CASH FLOW
Cash From Operating Activities -$58.97M -$98.43M
Capital Expenditures $2.288M $442.0K
Free Cash Flow -$61.26M -$98.87M
YoY Change -30.12% -4.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
30466000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
16740000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
47644000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32405000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P18M
iova Increase Decrease In Operating Lease Liability And Right Of Use Asset
IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
11200000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
69123000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
62515000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11436000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7777000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69246000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67085000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
80682000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
74862000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3996000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
4521000
us-gaap Operating Lease Cost
OperatingLeaseCost
7793000
us-gaap Operating Lease Cost
OperatingLeaseCost
9044000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1102000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
2307000
us-gaap Variable Lease Cost
VariableLeaseCost
2710000
us-gaap Variable Lease Cost
VariableLeaseCost
4001000
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
132000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
109000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001425205
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
297305999
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36860
dei Entity Registrant Name
EntityRegistrantName
IOVANCE BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
75-3254381
dei Entity Address Address Line1
EntityAddressAddressLine1
825 Industrial Road, Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
San Carlos
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94070
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
260-7120
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000041666
dei Trading Symbol
TradingSymbol
IOVA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
303513872
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228678000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114888000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
74000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
31604000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
151000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
183864000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
164979000
CY2024Q2 us-gaap Inventory Net
InventoryNet
27854000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10372000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10183000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17458000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
482257000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
307848000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110960000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114030000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
295299000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
229258000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
69123000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
62515000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
6356000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
66430000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
327000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
270000
CY2024Q2 us-gaap Assets
Assets
964322000
CY2023Q4 us-gaap Assets
Assets
780351000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
20416000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
33123000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61787000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69406000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11436000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7777000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
93639000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
110306000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69246000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67085000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
31897000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
17347000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
1000000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1000000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
102143000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
85432000
CY2024Q2 us-gaap Liabilities
Liabilities
195782000
CY2023Q4 us-gaap Liabilities
Liabilities
195738000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
297305999
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
297305999
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
256135715
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
256135715
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
526000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2526000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2990451000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2594448000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2222452000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2012375000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
768540000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
584613000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
964322000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
780351000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31106000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31106000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
31368000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
2050000
us-gaap Cost Of Revenue
CostOfRevenue
38629000
us-gaap Cost Of Revenue
CostOfRevenue
2050000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62084000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86347000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
141867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169081000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39568000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21927000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
70961000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50049000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
133020000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
110324000
us-gaap Costs And Expenses
CostsAndExpenses
251457000
us-gaap Costs And Expenses
CostsAndExpenses
221180000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-101914000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-110086000
us-gaap Operating Income Loss
OperatingIncomeLoss
-219636000
us-gaap Operating Income Loss
OperatingIncomeLoss
-220942000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3355000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3081000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6693000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6567000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-98559000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-107005000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-212943000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-214375000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1458000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-477000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2866000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-477000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-97101000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-106528000
us-gaap Net Income Loss
NetIncomeLoss
-210077000
us-gaap Net Income Loss
NetIncomeLoss
-213898000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
284817
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
284817
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
224481
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
224481
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
275518
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
275518
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
219117
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
219117
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-97101000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-106528000
us-gaap Net Income Loss
NetIncomeLoss
-210077000
us-gaap Net Income Loss
NetIncomeLoss
-213898000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
118000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
894000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
390000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
333000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1951000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
333000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96691000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-106077000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-212077000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-212671000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
680024000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31830000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1562000
CY2024Q2 iova Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensations Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationsNet
-1001000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
390000
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
152426000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
390000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-97101000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
768540000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
666881000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16740000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1271000
CY2023Q2 iova Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensations Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationsNet
-301000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
118000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
333000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-106528000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
578569000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
584613000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49603000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1562000
iova Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensations Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationsNet
-5701000
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
349786000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
754000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1951000
us-gaap Net Income Loss
NetIncomeLoss
-210077000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
768540000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
499638000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32405000
iova Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensations Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationsNet
-2230000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1271000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
260101000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
894000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
333000
us-gaap Net Income Loss
NetIncomeLoss
-213898000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
578569000
us-gaap Net Income Loss
NetIncomeLoss
-210077000
us-gaap Net Income Loss
NetIncomeLoss
-213898000
us-gaap Share Based Compensation
ShareBasedCompensation
47644000
us-gaap Share Based Compensation
ShareBasedCompensation
32405000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
86000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
181000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10119000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1933000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4689000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5910000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5963000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5695000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2866000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-477000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4834000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
855000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5677000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7065000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
31453000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15594000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
9549000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5478000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5261000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-16205000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3171000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8207000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5562000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-220708000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-193767000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
202000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
226633000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
216101000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
5323000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
52573000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
209509000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4613000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15184000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71287000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3383000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5701000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2230000
iova Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
1562000
iova Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
1271000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
754000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
349786000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
260101000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
346401000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
259197000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-616000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3768000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53790000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
58279000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181318000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
238161000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235108000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
296440000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
222637000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-49000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
894000
iova Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense
AcquisitionsOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpense
-2342000
iova Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense
AcquisitionsOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpense
-3813000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
23495000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
0
iova Non Cash Investing Activities Accrued Capitalized Acquisition Costs
NonCashInvestingActivitiesAccruedCapitalizedAcquisitionCosts
0
iova Non Cash Investing Activities Accrued Capitalized Acquisition Costs
NonCashInvestingActivitiesAccruedCapitalizedAcquisitionCosts
3440000
iova Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
0
iova Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
Rightofuseassetobtainedinexchangeforoperatingleaseliabilityfromnewleases
177000
iova Right Of Use Asset Obtained In Exchange For Operating Lease Liability From Lease Modifications
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityFromLeaseModifications
11297000
iova Right Of Use Asset Obtained In Exchange For Operating Lease Liability From Lease Modifications
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityFromLeaseModifications
349000
CY2024Q2 iova Cash Cash Equivalents And Short Term Investments And Restricted Cash Total
CashCashEquivalentsAndShortTermInvestmentsAndRestrictedCashTotal
419000000.0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228700000
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
183900000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
6400000
us-gaap Net Income Loss
NetIncomeLoss
-210100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-220700000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
6400000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
66400000
CY2024Q2 iova Minimum Restricted Security Deposit
MinimumRestrictedSecurityDeposit
5450000
CY2024Q1 iova Payments Of Contingent Consideration For Asset Acquisition
PaymentsOfContingentConsiderationForAssetAcquisition
52600000
CY2024Q1 iova Payments Of Contingent Consideration For Asset Acquisition
PaymentsOfContingentConsiderationForAssetAcquisition
41700000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228678000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230010000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
6430000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
66430000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235108000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
296440000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33907811
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26756143
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The </span><span style="font-style:normal;font-weight:normal;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include assumptions made in the fair value of intangible assets, inventories acquired as part of the acquisition of </span><span style="font-style:normal;font-weight:normal;">Proleukin</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">®</sup><span style="font-style:normal;font-weight:normal;">, equity awards and related stock-based compensation, assumptions used in measuring operating right-of-use assets and operating lease liabilities, accounting for potential liabilities, including estimates inherent in accruals related to clinical trials, and the realizability of the Company’s deferred tax assets</span><span style="font-style:normal;font-weight:normal;">.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
245758000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
245747000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
198993000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
199032000
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
61883000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
34053000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
183864000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
164979000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
245747000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
199032000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
0
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2024Q1 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
17500000
CY2024Q1 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
13900000
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
315361000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
239264000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
20062000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10006000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
295299000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
229258000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1900000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
10800000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
21700000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
21600000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
21500000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
21500000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
188000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
154000
CY2024Q2 us-gaap Lease Cost
LeaseCost
5230000
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12980000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6062000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5749000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8812000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4623000
CY2024Q2 us-gaap Inventory Net
InventoryNet
27854000
CY2023Q4 us-gaap Inventory Net
InventoryNet
10372000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31106000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
CY2024Q2 iova Revenue From Contract With Customer Gross
RevenueFromContractWithCustomerGross
32633000
CY2023Q2 iova Revenue From Contract With Customer Gross
RevenueFromContractWithCustomerGross
238000
iova Revenue From Contract With Customer Gross
RevenueFromContractWithCustomerGross
33352000
iova Revenue From Contract With Customer Gross
RevenueFromContractWithCustomerGross
238000
CY2024Q2 iova Adjustments For Government Rebates And Chargebacks
AdjustmentsForGovernmentRebatesAndChargebacks
51000
iova Adjustments For Government Rebates And Chargebacks
AdjustmentsForGovernmentRebatesAndChargebacks
51000
CY2024Q2 iova Adjustments For Wholesaler Fees And Cash Discounts
AdjustmentsForWholesalerFeesAndCashDiscounts
931000
iova Adjustments For Wholesaler Fees And Cash Discounts
AdjustmentsForWholesalerFeesAndCashDiscounts
935000
CY2024Q2 iova Adjustments For Other Rebates Returns Discounts And Adjustments
AdjustmentsForOtherRebatesReturnsDiscountsAndAdjustments
545000
iova Adjustments For Other Rebates Returns Discounts And Adjustments
AdjustmentsForOtherRebatesReturnsDiscountsAndAdjustments
545000
CY2024Q2 iova Revenue From Contract With Customer Gross To Net Adjustments
RevenueFromContractWithCustomerGrossToNetAdjustments
1527000
iova Revenue From Contract With Customer Gross To Net Adjustments
RevenueFromContractWithCustomerGrossToNetAdjustments
1531000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31106000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31106000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
CY2023Q2 us-gaap Lease Cost
LeaseCost
6937000
us-gaap Lease Cost
LeaseCost
10691000
us-gaap Lease Cost
LeaseCost
13199000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31821000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
238000
iova Threshold For Concentration Of Credit Risk
ThresholdForConcentrationOfCreditRisk
0.10
CY2024Q2 iova Revenue From Contract With Customer Gross To Net Adjustments
RevenueFromContractWithCustomerGrossToNetAdjustments
1527000
iova Revenue From Contract With Customer Gross To Net Adjustments
RevenueFromContractWithCustomerGrossToNetAdjustments
1531000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31106000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31821000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
144836000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
141943000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
33876000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27913000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110960000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114030000
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3000000.0
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6000000.0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5700000
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
4291000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
4235000
us-gaap Operating Lease Payments
OperatingLeasePayments
8581000
us-gaap Operating Lease Payments
OperatingLeasePayments
8396000
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
177000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
177000
iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
11297000
iova Increase Decrease In Right Of Use Assets From Lease Modifications
IncreaseDecreaseInRightOfUseAssetsFromLeaseModifications
349000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y8M23D
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
24977000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
34814000
CY2024Q2 iova Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
9391000
CY2023Q4 iova Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
10911000
CY2024Q2 iova Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
9479000
CY2023Q4 iova Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
10893000
CY2024Q2 iova Commercial Manufacturing Facility Related Current
CommercialManufacturingFacilityRelatedCurrent
1689000
CY2023Q4 iova Commercial Manufacturing Facility Related Current
CommercialManufacturingFacilityRelatedCurrent
2437000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2999000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1610000
CY2024Q2 iova Accrued Inventory Current
AccruedInventoryCurrent
9561000
CY2023Q4 iova Accrued Inventory Current
AccruedInventoryCurrent
2148000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3691000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6593000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61787000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69406000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000041666
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
297305999
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
23014000
CY2024Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
9.15
CY2024Q1 iova Net Proceeds From Public Offering
NetProceedsFromPublicOffering
197400000
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
23000000
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3000000
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
7.50
CY2023Q3 iova Net Proceeds From Public Offering
NetProceedsFromPublicOffering
161500000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y11M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.077
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.39
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
94900000
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
30466000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
16740000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
47644000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32405000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8692000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16937000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7989000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8186000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8389000
CY2024Q2 iova Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
75438000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
125631000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
44949000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
80682000
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;text-decoration-line:none;"><span style="display:inline-block;visibility:hidden;width:0pt;">​</span><br/></span><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NOTE 13. LEGAL PROCEEDINGS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shumacher Derivative Lawsuit.</span> On December 11, 2020, a purported stockholder derivative complaint was filed by plaintiff Leo Shumacher against the Company, as nominal defendant, and then current directors, as defendants, in the Court of Chancery in the State of Delaware (the “Court of Chancery”). The complaint alleges breach of fiduciary duty and a claim for unjust enrichment in connection with alleged excessive compensation of certain non-executive directors of the Company and seeks unspecified damages on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">behalf of the Company. The parties agreed to a proposed settlement, which was submitted to the Court of Chancery on June 15, 2022. After a hearing on November 17, 2022, the Court of Chancery required the parties to take additional steps before it would approve the settlement. The Company, as nominal defendant, and its current directors, as defendants, answered the complaint on February 3, 2023. The parties agreed to a revised proposed settlement, which was submitted to the Court of Chancery on March 12, 2024. Under the terms of the proposed settlement, the Company will cancel certain equity awards made to non-employee directors and make a monetary payment to plaintiff for reasonable legal fees and costs in the amount of </span>$600,000, which have been accrued as of June 30, 2024. On July 17, 2024, the Court of Chancery declined to approve the settlement. The case will proceed to discovery and the Company intends to vigorously defend itself against this complaint. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Solomon Capital, LLC.</span> On April 8, 2016, a lawsuit (“the First Solomon Suit”) titled <i style="font-style:italic;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</i> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff (“Solomon Plaintiffs”) against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016) (the “court”). The Solomon Plaintiffs allege that, between June and November 2012, they provided the Company $0.1 million and that they advanced and paid on behalf of the Company an additional $0.2 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 1,110 shares to the Solomon Plaintiffs (after the <span style="-sec-ix-hidden:Hidden_q_WT4N63VEaTAwkNhmoV3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-100</span></span> reverse split of the Company’s common stock effected in March 2013) (the “Equity Claim”), and (iii) allow the Solomon Plaintiffs to convert the foregoing funds into its securities in the next financing of the Company on the same terms offered to other investors, which Solomon Plaintiffs allege, should have given them the right to convert their advances and payments into shares of the Company’s common stock in the restructuring that took effect in May 2013. Based on the foregoing, the Solomon Plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest. On June 3, 2016, the Company filed an answer and counterclaims in the lawsuits. The Company has asserted counterclaims for fraudulent inducement, fraudulent misrepresentation, fraudulent concealment, breach of fiduciary duty, and breach of contract, alleging principally that the counterclaim defendants misrepresented their qualifications and failed to disclose that Solomon Sharbat was the subject of an investigation by the Financial Industry Regulatory Authority (“FINRA”) that resulted in the loss of his FINRA license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">In its counterclaims, the Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the Solomon Plaintiffs contend entitled them to obtain shares of Company stock. On May 12, 2020, the court granted the Company’s motion for summary judgment limiting the Solomon Plaintiffs’ damages for the Equity Claim to less than $47,420. The Solomon Plaintiffs filed a notice of appeal of this summary judgment on June 9, 2020. On July 2, 2020, the court granted the Company’s motion to dismiss the First Solomon Suit for want of prosecution. On January 4, 2021, the court granted the Solomon Plaintiffs motion for reconsideration, and reinstituted the case. On January 15, 2021, the Company filed a notice of appeal of the court’s grant of the Solomon Plaintiffs motion for reconsideration. On May 11, 2021, the Appellate Division upheld the court’s grant of the Solomon Plaintiffs’ motion for reconsideration of the dismissal of the First Solomon Suit for want of prosecution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt;">On September 27, 2019, the Solomon Plaintiffs filed a new lawsuit (through new legal counsel) (“the Second Solomon Suit”) titled Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Iovance Biotherapeutics, Inc., f/k/a/ Lion Biotechnologies Inc. f/k/a/ Genesis Biopharma Inc., and Manish Singh in the Supreme Court of the State of New York, County of New York (index no. 655668/2019). In the Second Solomon Suit, the Solomon Plaintiffs allege that they are third party beneficiaries of a “finder’s fee agreement” that prior management entered into with a third party unlicensed entity in 2012 in connection with seeking financing, that an agreement or understanding existed between the Company and the plaintiffs that the plaintiffs would be paid fees and commissions (in cash and stock) if they obtained financing for the Company, and that they directly and indirectly introduced investors to the Company who invested in the Company, or were willing to invest in the Company. Finally, the Solomon Plaintiffs allege that they were promised a license to use the Company’s technology in Israel. The plaintiffs claim that the Company breached the foregoing understandings, promises and agreements and, as a result, they are entitled to certain damages. The Solomon Plaintiffs also allege that Manish Singh, the Company’s former Chief Executive Officer, committed fraud and took shares belonging to them. On February 18, 2020, the Company filed a removal petition and removed the Second Solomon Suit to the U.S. District Court for the Southern District of New York (the “District Court”), where the case has been assigned case no. 1:20-cv-1391. On May 22, 2020, the Company moved to dismiss the Second Solomon Suit for lack of personal jurisdiction. On March 26, 2021, the District Court denied the Company’s motion to dismiss for lack of personal jurisdiction. The Company filed a response to the complaint in the Second Solomon Suit on April 30, 2021. On May 26, 2021, the Company and Singh filed motions for judgment on the pleadings with respect to the second and third claims asserted against the Company and all claims asserted against Singh, respectively, in the Second Solomon Suit. On January 5, 2022, the District Court granted the Company’s motions for judgment on the pleadings, dismissing the second and third claims against the Company and dismissing all claims against Singh. On January 4, 2023, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">the District Court granted in part the Company’s motion for sanctions against the Solomon Plaintiffs for violating Rule 11 of the Federal Rules of Civil Procedure, in a decision and order that dismissed the Solomon Plaintiffs’ first claim against the Company, denied the Solomon Plaintiffs’ motion for leave to amend the complaint, and ordered the Solomon Plaintiffs to pay the Company’s attorneys’ fees incurred in connection with the Rule 11 motion. Following the District Court’s decision and order on the Rule 11 motion, only the Solomon Plaintiffs’ fifth and sixth claims, for unjust enrichment and indemnification, respectively, remain pending against the Company. On October 26, 2023, the District Court granted the Company’s motion for summary judgment and dismissed the Solomon Plaintiffs’ fifth and sixth claims. On October 27, 2023, the District Court entered judgment for the Company and closed the Second Solomon Suit. On November 10, 2023, the Company filed a motion for attorneys’ fees as the prevailing party in the action. On December 1, 2023, the Solomon Plaintiffs filed a notice of appeal to the U.S. Court of Appeals for the Second Circuit (the “Second Circuit Court”), appealing the District Court’s orders (a) granting the motions for judgment on the pleadings filed on behalf of Singh and the Company, (b) granting the Company’s Rule 11 motion, (c) denying the Solomon Plaintiffs’ motions to compel discovery and re-open discovery, and (d) granting the Company’s summary judgment motion. On December 22, 2023, the Company filed a motion for an order requiring the Solomon Plaintiffs to post an appeal bond, to ensure payment of the Company’s appellate fees and costs should the Company prevail on the appeal. On May 9, 2024, the District Court issued an order granting the Company’s motions for attorneys’ fees and for an appeal bond. On June 28, 2024, the Company filed motions to dismiss the appeal on the grounds that the Solomon Plaintiffs (a) do not have an opening brief on file, which the Second Circuit Court denied, and (b) have not filed an appeal bond, which remains pending.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">The Company intends to vigorously defend these complaints and pursue its counterclaims, as applicable. At the current stage of the litigation, in both the First Solomon Suit and the Second Solomon Suit, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.35pt;margin:0pt 0pt 10pt 0pt;">The Company has been and may continue to be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that it believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on its financial position, results of operations or cash flows.</p>
CY2024Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
600000
CY2020Q2 iova Equity Claim
EquityClaim
47420000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2900000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.015
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.013
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-500000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001558370-24-011641-index-headers.html Edgar Link pending
0001558370-24-011641-index.html Edgar Link pending
0001558370-24-011641.txt Edgar Link pending
0001558370-24-011641-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
iova-20240630.xsd Edgar Link pending
iova-20240630x10q.htm Edgar Link pending
iova-20240630xex10d1.htm Edgar Link pending
iova-20240630xex10d2.htm Edgar Link pending
iova-20240630xex31d1.htm Edgar Link pending
iova-20240630xex31d2.htm Edgar Link pending
iova-20240630xex32d1.htm Edgar Link pending
iova-20240630xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
iova-20240630_cal.xml Edgar Link unprocessable
iova-20240630_def.xml Edgar Link unprocessable
iova-20240630_lab.xml Edgar Link unprocessable
iova-20240630_pre.xml Edgar Link unprocessable
iova-20240630x10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending